Lilly wins first-ever FDA approval for drug that can spot Alzheimer's 'tau tangles'

In Alzheimer's disease research, the lion's share of time and resources has gone toward a protein called amyloid, which many have believed to be the root cause of patients' declining brain function. But there's another protein, tau, that has drawn interest as well. Investigating tau-targeting drugs may soon be easier too, as the Food and Drug Administration on Thursday approved an imaging agent that shows how much tau is in a patient's brain.